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The energy-generating membrane protein NADH dehydrogenase
(NDH-2), a proposed antibacterial drug target (see “Inhibitors of type
II NADH:menaquinone oxidoreductase represent a class of anti-
tubercular drugs” Weinstein et al. 2005 [1]), was screened for mod-
ulators of activity in either detergent-solublised or lipid reconstituted
(proteolipsome) form. Here we present an annotated list of com-
pounds identiﬁed in a small-scale screen against NDH-2. The dataset
contains information regarding the libraries screened, the identities
of hit compounds and the physicochemical properties governing
solubility and permeability. The implications of these data for future
antibiotic discovery are discussed in our associated report, “Com-
parison of lipid and detergent enzyme environments for identifying
inhibitors of membrane-bound energy-transducing proteins” [2].
& 2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
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areaAntibiotic discovery, drug discovery, microbiologyype of data Table
ow data was
acquiredSpectrophotometry using Varioskans Flash (Thermo Scientiﬁc) 96-well plate
reader.ata format Analysed and annotated with physicochemical properties
xperimental factors Type II NADH dehydrogenase was puriﬁed and either remained in detergent
solubilized form or reconstituted into proteoliposome form.
xperimental
featuresSpectrophotometric determination of NADH oxidation at 340 nmata source location University of Otago, Dunedin, New Zealand
ata accessibility Data in articleValue of the data
 The respiratory Type II NADH dehydrogenase (NDH-2) is an antimicrobial drug target and these
annotated drug screening data provide information that may be used for further antimicrobial drug
development.
 These data provide the identity of compounds from three libraries that either inhibit or stimulate
NDH-2 activity in both detergent-solubilsed and lipid-reconstituted forms.
 The list of compounds is further annotated with ‘Rule of Five’ properties that may be used to inform
future antimicrobial drug discovery and development.1. Data
These data are the annotated hits identiﬁed by screening both detergent-solubilised (DS) and
lipid-reconstituted (LR) respiratory Type II NADH dehydrogenase. The table contains the library;
compound name, number of H-bond donors/acceptors, molecular weight, lipophilicity (logP) and
degree of inhibition/stimulation for DS and LR protein (Table 1).2. Experimental design, materials and methods
Type II NADH dehydrogenase (NDH-2) was puriﬁed and reconstituted into proteoliposomes as
described by Dunn et al. [2,3]. Detergent-solubilised (DS) NDH-2 or lipid-reconstituted (LR) NDH-2
were screened by end point 96-well assay (340 nm, Varioskans Flash Thermo Scientiﬁc, in the pre-
sence of 100 μM menadione and 20 μM test compound. The reaction was initiated using 200 μM
NADH. Screening was carried out in technical triplicate against each compound library. NADH:
menadione oxidoreductase inhibition/stimulation was calculated as a percentage of control activity
for either DS or LR protein [2]. Compounds showing inhibition (r70% control) or activation (Z130%
control) in at least 2 of the 3 independent screening replicates were considered hits. Compound
libraries screened were Library of Pharmacologically Active Compounds (LOPAC, SigmaAldrich), the
Natural Products Set II (National Institutes of Health, USA) and the Quinolinequinone Library
(Malaghan Institute of Medical Research, NZ) [4]. Hits were annotated with library of origin, chemical
name and the drug-like properties governing in vivo absorption as described by the ‘Rule of Five’
namely, lipophilicity (logP), molecular weight, hydrogen bond donor and hydrogen bond acceptors
[5]. Where necessary logP was predicted using ALOGPS software provided by the Virtual Computa-
tional Chemistry Laboratory [6].
Table 1
Inhibitors/activators of detergent-solubilized (DS) or lipid-reconstituted (LR) NDH-2 activity, detected by screening compound
libraries.
Librarya Compound name H-bond
donorsb
H-bond
acceptorsb
Molecular
weight
LogPb % control
activity
DSc
% control
activity LRc
LOPAC I-OMe-Tyrphostin AG 538 3 5 437.19 2 4076.7 41.9727.0
LOPAC Myricetin 6 8 318.24 0 42714.2 29.9722.4
LOPAC Morin 5 7 302.24 2 32731.2 18.7712.1
LOPAC Nordihydroguaiaretic acid (NDGA) 4 4 302.37 4 33724.4 18.7723.1
LOPAC Reactive blue 2 5 11 840.11 1* 4477.3 36.53744.5
LOPAC Tyrphostin AG 538 4 5 297.27 1 3777.4 38.1728.2
LOPAC Tyrphostin AG 698 3 3 308.34 1 6372.1 67.672.3
LOPAC Tyrphostin AG 528 2 3 308.34 3 54721.2 55.3715.9
LOPAC Indirubin-30-oxime 3 2 277.28 2 50712.1 47.6725.6
LOPAC Hispidin 3 5 246.22 0 4873.2 53.7719.4
LOPAC Tyrphostin AG 537 6 6 448.44 1 22718.4 57.0716..9
LOPAC 2,6-Diﬂuoro-4-[2-(phenylsulfony-
lamino) ethylthio]phenox-
yacetamide (PEPA)
3 4 402.44 2 13673.1 133.7715.2
LOPAC Caffeic acid phenethyl ester 2 4 284.31 4 4379.0 N/A
LOPAC Piceatannol 4 4 244.25 3 3575.5 N/A
LOPAC Tyrphostin AG 808 3 3 304.31 2 7716.5 N/A
LOPAC 4-Chloromercuribenzoic acid 1 2 257.16 2* 4870.3 N/A
LOPAC WIN 62,577 1 1 438.58 5 14271.8 N/A
LOPAC MJ33 1 7 514.49 8* 149722.7 N/A
LOPAC Pentylenetetrazole 0 0 138.17 0 13272.9 N/A
LOPAC Kenpaullone 2 1 327.18 5 6572.9 N/A
LOPAC Pregnenolone sulphate sodium 0 5 418.53 1* 6871.1 N/A
LOPAC Phloretin 4 2 274.28 1 6573.8 N/A
LOPAC Farnesylthiosalicylic acid 1 2 358.55 7 6171.4 N/A
LOPAC Tyrphostin AG 555 3 3 322.37 3 5371.2 N/A
LOPAC Suramin hexasodium 6 23 1429.19 3* 61710.0 N/A
LOPAC Rottlerin 5 8 516.55 1* 5776.1 N/A
NIH 6H-Benzofuro[3,2-c] [1] benzo-
pyran-6-one, 3,9-dihydroxy-
ND ND 268.23 ND 65722.2 N/A
NIH 6H-Pyrido[4,3-b]carbazole, 5,11-
dimethyl-
ND ND 246 ND 65728.1 N/A
NIH Michellamine B diacetic acid salt ND ND 877 ND 54731.2 N/A
NIH [9,90-bi-4H-Naphtho[2,3-b]pyran]-
4,40-dione, 2,20 ,3,30-tetrahydro-
5,50 ,6,60 ,8,80-hexahydroxy-2,20 ,3,30-
tetramethyl-
ND ND 547 ND 33711.5 N/A
NIH Mangostin ND ND 410 ND 19715.3 N/A
Quinonolone
Quinone
Compound 18b ND ND 375.46 ND 41722.7 46719.8
Quinonolone
Quinone
Compound 19 ND ND 377.48 ND 36716.1 3875.1
a Compound libraries were screened for inhibitors of NDH-2 NADH oxidation. Libraries screened included the Library of
Pharmacologically Active Compounds (LOPAC), The NIH (National Institutes of Health) Natural Products Set II, and the Qui-
nolinequinone Library.
b ND¼value not determined.
c Data variation is expressed as standard deviation, N/A¼not applicable.
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